Juli DeGraw

Juli is the Vice President of CMC and Product Development at IconOVir Bio. Prior to IconOVir she was Managing Director of the Life Science Consulting Group, L.L.C. supporting CMC due diligence, IND packages and GMP manufacturing strategies for clients including Dr. Clodagh O’Shea at the Salk Institute for Biological Studies. Juli joined the Department of Oncology […]

Michael Lyman

Michael Lyman is the Vice President of Discovery Research at IconOVir Bio. Prior to joining IconOVir, Michael was the Director of Translational Research at the Salk Institute of Biological Studies where he led a translational research team working with Clodagh O’Shea to develop a pipeline of novel virus-based therapies including oncolytic viruses. Before going to the […]

Heba Nowyhed, Ph.D.

Heba Nowyhed is the Senior Vice President of Research at IconOVir Bio. She joined IconOVir from Vida Ventures, where she was a Senior Associate conducting scientific due diligence on investment opportunities in the Biotech space, and supporting portfolio companies. Previously she was at Kite, where she and her team played a key role in generating non-clinical data […]

Christopher Wilfong

Christopher Wilfong is a Corporate Development and Strategy Advisor to IconOVir Bio. In addition, Mr. Wilfong is an Operating Partner at Two River Consulting, LLC, where he has been a co-founder and held senior leadership roles in multiple Two River portfolio companies, including Kite Pharma, Inc., Kronos Bio, Inc., and Neogene Therapeutics, Inc. Prior to […]

Sean Algeo, CPA

Sean Algeo is the Treasurer and Corporate Controller of IconOVir Bio. He also serves as Chief Financial Officer at Two River Consulting, LLC, where he is responsible for all financial and accounting activities of Two River and certain of its portfolio companies. Prior to joining Two River in 2018, Mr. Algeo was a Senior Manager […]

David Tanen

David Tanen is a co-founder and Corporate Secretary of IconOVir Bio. David is also a co-founder and Partner of Two River, which focuses on creating, operating and financing development stage life science companies. David was also a co-founder of Kite Pharma, Inc., where he served as Corporate Secretary and General Counsel until its acquisition by […]

Joshua Kazam

Joshua Kazam is a co-founder and director of IconOVir Bio. Josh is also a co-founder and director of Kronos Bio, Inc. (KRON), and Allogene Therapeutics, Inc. (ALLO), and is a co-founder and Partner of Two River, where he has served as partner since its inception in 2004. He is a co-founder and partner of Vida […]

Frank McCormick, Ph.D., FRS, DSc (Hon)

Frank McCormick, PhD, is a Professor at the UCSF Helen Diller Family Comprehensive Cancer Center. Prior to joining the UCSF faculty, Dr. McCormick pursued cancer-related work with several Bay Area biotechnology firms and held positions with Cetus Corporation (Director of Molecular Biology, 1981-1990; Vice President of Research, 1990-1991) and Chiron Corporation, where he was Vice […]

Arie Belldegrun, M.D.

Arie Belldegrun, M.D., is a co-founder and Director of IconOVir Bio. He is also Executive Chairman and co-founder of Allogene Therapeutics, Inc. (ALLO), a clinical stage biotechnology company focused on pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. A visionary entrepreneur, Arie founded Kite Pharma, a biopharmaceutical company […]

Mark Chao, M.D., Ph.D.

Mark Chao is a physician-scientist and biotech entrepreneur with over 20 years of experience in oncology research. He was a co-founder and SVP of clinical development at Forty Seven, Inc., an immuno-oncology company developing macrophage-directed therapeutics which was acquired by Gilead Sciences for $4.9B in 2020. As one of the scientific pioneers discovering CD47, an anti-phagocytic signal, as a […]